Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Liu, H ^a   Lu, J ^a   Hua, Y ^b   Zhang, P ^a   Liang, Z ^a   Ruan, L ^a   Lian, C ^a   Shi, H ^a   Chen, K ^a   Tu, Z ^a  

^a JIANGSU UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 1; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GANETESPIB; HEAT SHOCK PROTEIN 90; HEMATOXYLIN; KI 67 ANTIGEN; SMALL INTERFERING RNA; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG INHIBITION; DRUG SENSITIVITY; DRUG TARGETING; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE, NUDE; MOLECULAR TARGETED THERAPY; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927616700     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.555     Document Type: Article

References (44)

1. Stewart BW, Wild CP World Cancer Report, 2014. IARC Publication: Lyon, France.
2. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA et al. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10: 643-655.
3. Kim HJ, Eun JY, Jeon YW, Yun J, Kim KH, Kim SH et al. Efficacy and safety of oxaliplatin, 5-fluorouracil, and folinic acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer. Cancer Res Treat 2011; 43: 154-159.
4. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587-595.
5. Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of METactivation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010; 9: 1188-1197.
6. An JY, Kim KM, Choi MG, Noh JH, Sohn TS, Bae JM et al. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 2010; 126: 2904-2913.
7. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 2014; 465: 25-33.
8. Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M et al. Amplification/ overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep 2004; 12: 593-599.
9. Wang J, Yang S, Zhang H, Song Y, Zhang X, Qian H et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011; 26: 23-32.
10. Honma K, Nakanishi R, Nakanoko T, Ando K, Saeki H, Oki E et al. Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surg Today 2014; 44: 454-461.
11. Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I et al. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res 2013; 19: 5053-5067.
12. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18: 64-76.
13. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008; 8: 370-374.
14. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-549.
15. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NYAcad Sci 2007; 1113: 202-216.
16. Wang J, Cui S, Zhang X, Wu Y, Tang H. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS One 2013; 8: e62876.
17. Kang GH, Lee EJ, Jang KT, Kim KM, Park CK, Lee CS et al. Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours. Histopathology 2010; 56: 694-701.
18. Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle 2012; 11: 3649-3655.
19. Solier S, Kohn KW, Scroggins B, Xu W, Trepel J, Neckers L et al. Heat shock protein 90alpha (HSP90alpha), a substrate and chaperone of DNA-PK necessary for the apoptotic response. Proc Natl Acad Sci USA 2012; 109: 12866-12872.
20. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heatshock proteins in human tumor cells. Int J Cancer 1992; 51: 613-619.
21. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007; 98: 1536-1539.
22. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410.
23. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6: 1123-1132.
24. Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 2011; 102: 1388-1395.
25. Horibe T, Kohno M, Haramoto M, Ohara K, Kawakami K. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 2011; 9: 8.
26. Choi HK, Lee K. Recent updates on the development of ganetespib as a Hsp90 inhibitor. Arch Pharm Res 2012; 35: 1855-1859.
27. Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res 2014; 74: 1294-1300.
28. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11: 475-484.
29. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13: 38-43.
30. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2014; e-pub ahead of print 29 October 2014.
31. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
32. Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K et al. HSP90 and its inhibitors. Oncol Rep 2010; 23: 1483-1492.
33. Taldone T, SunW, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009; 17: 2225-2235.
34. Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov 2014; 9: 1-20.
35. Messaoudi S, Peyrat JF, Brion JD, Alami M. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin Ther 2011; 21: 1501-1542.
36. Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK et al. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol 2013; 85: 1246-1256.
37. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D et al. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther 2013; 12: 509-519.
38. Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther 2012; 11: 730-739.
39. Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y et al. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 2012; 103: 342-349.
40. Yeo M, Park HK, Lee KM, Lee KJ, Kim JH, Cho SW et al. Blockage of HSP 90 modulates Helicobacter pylori-induced IL-8 productions through the inactivation of transcriptional factors of AP-1 and NF-kappaB. Biochem Biophys Res Commun 2004; 320: 816-824.
41. Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinibsensitive and -resistant MET-driven tumor models. Cancer Res 2013; 73: 7022-7033.
42. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013; 19: 3671-3680.
43. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
44. Chou T-C, Talalay P. Analysis of combined drug efffects: a new look at a very old problem. Trends Pharmacol Sci 1983; 4: 450-454.